Reuters logo
BRIEF-Kite Pharma submits IND application for KITE-585, anti-BCMA CAR-T therapy candidate
2017年8月8日 / 中午12点06分 / 2 个月前

BRIEF-Kite Pharma submits IND application for KITE-585, anti-BCMA CAR-T therapy candidate

Aug 8 (Reuters) - Kite Pharma Inc

* Kite submits investigational new drug (IND) application for KITE-585, anti-BCMA CAR-T therapy candidate for multiple myeloma

* Says submits ‍application with U.S. FDA to initiate a phase 1, first-in-human trial of KITE-585​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below